CD22 and acute lymphoblastic leukemia: Moreover, serum ADAM6 showed significant variation between CD22+ and CD22−, as well as CD45+ and CD45− ALL patients, while PRSS1 significantly varied between HLA-DR+ and HLA-DR− ALL patients.